Jazz to buy Actio Biosciences for $820 million upfront, up to $500 million more in milestones

• Jazz Pharmaceuticals agreed to buy privately held Actio Biosciences for USD 820 million upfront, with up to USD 500 million tied to milestones.
• Deal adds ABS-1230, a clinical-stage KCNT1 ion channel inhibitor for KCNT1+ epilepsy, a rare condition with no FDA-approved therapies.
• Actio will spin out a new private company at closing, leaving ABS-1230 with the acquired business; Jazz will take a minority stake.
• Transaction is expected to close in Q4 2026, funded with cash on hand and existing financing facilities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608100730PR_NEWS_USPR_____SF22348) on August 10, 2026, and is solely responsible for the information contained therein.